Kura Oncology (KURA) Revenue (2025 - 2026)
Kura Oncology's (KURA) quarterly Revenue came in at $18.3 million in Q1 2026, up 29.47% year-on-year from $14.1 million in Q1 2025, and up 5.36% on a QoQ basis from $17.3 million in Q4 2025.
Kura Oncology (KURA) Revenue (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of Revenue data on file, last reported at $18.3 million in Q1 2026.
- On a quarterly basis, Revenue rose 29.47% year-over-year to $18.3 million in Q1 2026; TTM through Mar 2026 was $71.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $67.5 million, up 25.24% from the prior year.
- Revenue for Q1 2026 stood at $18.3 million, up from $17.3 million in the prior quarter.
- Over the last five years, Revenue for KURA reached as high as $20.8 million in Q3 2025 and fell as low as $14.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Kura Oncology | 928.19 Mn | 928.19 Mn | 18.00 Mn | 18.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.27 Mn |
| Dec 31, 2025 | 17.34 Mn |
| Sep 30, 2025 | 20.75 Mn |
| Jun 30, 2025 | 15.29 Mn |
| Mar 31, 2025 | 14.11 Mn |